@article {BearblockPA3380, author = {Elizabeth Bearblock and Donna Mcshane and Helen Milroy and Stephanie Aldridge and Doxa Kotzia}, title = {Late Breaking Abstract - Lessons from introducing DEKAs as a means of vitamin supplementation in paediatric Cystic Fibrosis patients}, volume = {58}, number = {suppl 65}, elocation-id = {PA3380}, year = {2021}, doi = {10.1183/13993003.congress-2021.PA3380}, publisher = {European Respiratory Society}, abstract = {Introduction: In 2019/2020, we switched from using individual vitamin tablets to a single multi-vitamin: DEKAs for paediatric CF patients with pancreatic insufficiency. In the same timeframe CFTR modulator therapies were introduced.Aim: We compared patient{\textquoteright}s vitamin levels at their annual review the year prior to the introduction of DEKAs with levels the year after.Methods: If an individual had their annual review less than 3 months after they were advised to switch to DEKAs then their levels from the next year were used. We used student t-tests to quantify any changes.Results: There was no significant change in average Vitamin A, E or E: Cholesterol levels following the introduction of DEKAs. Average Vitamin D levels and PIVKA II significantly increased by 14.38 nmol/L. and 6.0 au/ml respectively, while average Vitamin K levels significantly decreased by 2.72 microgram/L. This was as expected as before the change individuals were routinely receiving 800-1500 micrograms of Vitamin D and 5-10mg of vitamin K daily while DEKAs contained 2000-3000 micrograms and 1mg of each respectively. There was no significant difference in response to DEKAs introduction on Vitamin A, E, E: cholesterol or D levels in those on CFTR modulators compared to those that were not. Vitamin K levels were more stable and PIVKA II levels less stable in individuals on a CFTR modulator.Conclusions: We conclude that additional Vitamin K supplementation may be required in patients using DEKAs as their sole source of supplementation. Serial Vitamin K and PIVKA II levels should be collected to confirm this and clarify the effect of CFTR modulators on these levels.FootnotesCite this article as: European Respiratory Journal 2021; 58: Suppl. 65, PA3380.This abstract was presented at the 2021 ERS International Congress, in session {\textquotedblleft}Prediction of exacerbations in patients with COPD{\textquotedblright}.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).}, issn = {0903-1936}, URL = {https://erj.ersjournals.com/content/58/suppl_65/PA3380}, eprint = {https://erj.ersjournals.com/content}, journal = {European Respiratory Journal} }